C18
Conditions
Interventions
Group 1: Each Patient will be treated according to his physicians therapeutic strategy - there is no intervention and no arming.
Tumor tissue will be tested for MSI and RAS, and we will collect releva
Sponsors
Institut für Pathologie der Ruhr-Universität Bochum
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients, treated at participating sites are eligible for participation if they fulfill all oft he following criteria: prospective enrollment: • Male or female patient with CC UICC stage I, II or III • Cooperating pathology willing to provide tissue samples for research according to study protocol • Age = 18 years and able to understand the concept of the registry and give informed consent • signed informed consent for registry participation according to ICH-GCP guidelines retrospective enrollment: • primary diagnosis since 1st January 2006 • other inclusion criteria according to protocoll version 5.1.1
Exclusion criteria
Exclusion criteria: patients that • do not fulfill inclusion criteria • withdraw consent to participate
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| 5-year RFS of MSI/KRAS WT patients versus MSS/KRAS MT patients with colon cancer stage II with risk factors OS, DFS of patients with colon cancer stage II RFS, DFS and OS of patients with colon cancer stage III explorative: Identify molecular signature for patients stage II without risk factors To identify patients that are clinically and/or molecularly eligible for interventional trials (optional). establish a participatory decision making strategy | — |
Primary
| Measure | Time frame |
|---|---|
| 5-year RFS of MSI/KRAS WT patients versus MSS/KRAS MT patients with colon cancer stage II without risk factors | — |
Countries
Germany
Contacts
Public ContactAndrea Tannapfel
Institut für Pathologie
Outcome results
None listed